Rev Cardiovasc Med. 2026 Jul 17;27(7):49021. doi: 10.31083/RCM49021. eCollection 2026 Jul.
ABSTRACT
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by asymmetric myocardial hypertrophy and is closely linked with myocardial fibrosis. The level and severity of myocardial fibrosis are independent risk factors for adverse clinical outcomes, including being closely related to sudden cardiac death, heart failure progression, and all-cause mortality. Advances in imaging technology have expanded HCM management beyond standard morphological assessment into a multidimensional paradigm that integrates molecular characterization, functional evaluation, and prognostic stratification. This paradigm shift supports an integrated clinical approach that enables early detection, targeted therapeutic intervention, and risk-adapted prevention strategies. Innovations in artificial intelligence (AI) are further transforming HCM management into an intelligent framework driven by data analytics, predictive modeling, and precision-guided interventions. Building on the pathophysiological basis of myocardial fibrosis, this review presents a comprehensive discussion of transformative developments in multimodal imaging technologies and the associated clinical applications, supported by an in-depth analysis of the recent AI-based advances in intelligent diagnostics, risk stratification, and therapies. Collectively, these concepts aim to optimize clinical decision-making and improve patient care practices.
PMID:42534370 | PMC:PMC13419953 | DOI:10.31083/RCM49021